In view of the high risk of recurrent disease in stage III and IV ovarian cancer following primary first-line chemotherapy,a variety of maintenance and consolidation treatment strategies have been developed.These have...In view of the high risk of recurrent disease in stage III and IV ovarian cancer following primary first-line chemotherapy,a variety of maintenance and consolidation treatment strategies have been developed.These have included:radiation,intravenous or intraperitoneal chemotherapy,targeted therapies,and immunotherapy.Popular at this time is the use of Poly-adenosine ribose polymerase(PARP)inhibitors and bevacizumab as maintenance therapy.What effect these maintenance or consolidation therapies have on subsequent response to therapy,specifically platinum-based chemotherapy,is only beginning to be studied.In this manuscript,we review the impact of PARP inhibitors and bevacizumab as well as radiation and maintenance chemotherapy on subsequent response to treatment.Prior use of bevacizumab does not appear to adversely affect subsequent response to platinum-based chemotherapy or platinum-based chemotherapy with bevacizumab.Prior therapy with PARP inhibitors induces platinum resistance to subsequent platinum-based therapy and negates classic predictors of response such as platinum-free interval and breast cancer susceptibility gene(BRCA)mutational status.展开更多
文摘In view of the high risk of recurrent disease in stage III and IV ovarian cancer following primary first-line chemotherapy,a variety of maintenance and consolidation treatment strategies have been developed.These have included:radiation,intravenous or intraperitoneal chemotherapy,targeted therapies,and immunotherapy.Popular at this time is the use of Poly-adenosine ribose polymerase(PARP)inhibitors and bevacizumab as maintenance therapy.What effect these maintenance or consolidation therapies have on subsequent response to therapy,specifically platinum-based chemotherapy,is only beginning to be studied.In this manuscript,we review the impact of PARP inhibitors and bevacizumab as well as radiation and maintenance chemotherapy on subsequent response to treatment.Prior use of bevacizumab does not appear to adversely affect subsequent response to platinum-based chemotherapy or platinum-based chemotherapy with bevacizumab.Prior therapy with PARP inhibitors induces platinum resistance to subsequent platinum-based therapy and negates classic predictors of response such as platinum-free interval and breast cancer susceptibility gene(BRCA)mutational status.
